Genetic modulation of rare earth nanoparticle biotransformation shapes biological outcomes.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40210885.
- Also identified by DOI 10.1038/s41467-025-58520-z and PMC identifier 11985947.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The biotransformation of nanoparticles plays a crucial role in determining their biological fate and responses. Although a few engineering strategies (e.g., surface functionalization and shape control) have been employed to regulate the fate of nanoparticles, the genetic control of nanoparticle biotransformation remains an unexplored avenue. Herein, we utilized a CRISPR-based genome-scale knockout approach to identify genes involved in the biotransformation of rare earth oxide (REO) nanoparticles. We found that the biotransformation of REOs in lysosomes could be genetically controlled via SMPD1. Specifically, suppression of SMPD1 inhibited the transformation of La<sub>2</sub>O<sub>3</sub> into sea urchin-shaped structures, thereby protecting against lysosomal damage, proinflammatory cytokine release, pyroptosis and RE-induced pneumoconiosis. Overall, our study provides insight into how to control the biological fate of nanomaterials.
Medical subject headings
- Metals, Rare Earth
- Nanoparticles
- Metal Nanoparticles